Healthcare & Life Sciences Blog -

Impact of MFN Pricing on Transactions

by Nadine Charrière, Shelly Kuo, Oren Livne, Dr. iur. Julia Schieber and Lois Sheng Liu

Healthcare Services

United States: HHS-OIG Issues Unfavorable Advisory Opinion on Physician Royalty Arrangements with Device Company

Pharmaceuticals & Biotech

United States: President Trump Tariffs on Patented Pharmaceuticals Under Section 232

by Patrick de Lapérouse, Jane E. Hobson, Oren Livne, Lois Sheng Liu, Chandri Navarro, Eunkyung Kim Shin, Christine Streatfeild, Randall B. Sunberg, Xin Tao and Lise S. Test

Pharmaceuticals & Biotech

The US BIOSECURE Act Becomes Law: Implications for Collaborations with “Biotechnology Companies of Concern”

by Janet K. Kim, Xin Tao, Lise S. Test and Bruce J. Linskens

Pharmaceuticals & Biotech

Manufacturing Site Divestitures: Best Practices for Successful Execution

by Michelle Carr, Daniel Garcia, Lois Sheng Liu and Xin Tao

Digital Health January 8, 2026

Medical Device AI in Limbo: EU’s Digital Overhaul or Digital Headache for Pharma and Medtech?

The EU ended 2025 with a legislative blitz – AI, cybersecurity, data use, data protection, and medical devices were all subject to proposals promising…

Medical Devices December 19, 2025

EU Biotech Act Unveiled: Commission’s Proposal to Turn Europe into a Biotech Powerhouse

Background On 16 December 2025, the European Commission published its long-awaited Proposal for a Biotech Act with an aim to “build a world-leading health…

Medical Devices December 19, 2025

The EU’s 2025 proposal to simplify the Medical and In-Vitro-Diagnostic Devices Regulations (MDR/IVDR)

On 16 December 2025, the European Commission published its proposal to simplify the EU’s Medical Devices Regulation (Regulation (EU) 2017/745) (MDR) and In Vitro…

Subscribe for Regular Alerts
<a href=https://bakerxchange.com/s/c52fd01a1d26bb8596eb85be3f6666b83a7d2dc5>View Survey</a>
Related Websites
HLS HUB
Archives
Archives

EU Pharmaceutical Package

In EU Pharmaceutical Package

A New Dawn for the EU Pharma Regulatory Regime? The Commission’s Proposal to Revise the EU Pharmaceutical Legislation is Finally Published

April 26, 2023 by Els Janssens, Magda Tovar and Julia Gillert 5 Mins Read

Today the European Commission has finally published its Proposal to revise the EU Pharmaceutical legislation, the most momentous…

In EU Pharmaceutical Package

EU Pharma Package: How Significant are the Proposals for Orphan Medicines?

May 16, 2023 by Els Janssens, Magda Tovar and Julia Gillert 6 Mins Read

On 26 April 2023 the European Commission published its Proposals to Reform the EU pharmaceutical legislation.[1] We continue…

In EU Pharmaceutical Package

Hungarian Pricing and Reimbursement Reforms Aiming to Remove Hurdles to Late Market Access of Innovative Pharmaceuticals

May 26, 2023 by Dr. Helga Bíró M.Jur. and Máté Laczkó 3 Mins Read

In brief Reimbursing medicinal products is critical to ensure that treatments are widely available to patients. This is…

In EU Pharmaceutical Package

The EU Pharmaceutical Package From a National Perspective: Member States’ First Reactions

May 30, 2023 by Els Janssens, Julie Yeni, Dr. Martin Altschwager LL.M., Dr. Frank Pflueger and Magda Tovar 6 Mins Read

The Proposal to revise the EU Pharmaceutical legislation has generated unprecedented levels of attention, not only across the…

In EU Pharmaceutical Package

The Future is Green: Eco Measures are Embedded into the EU Reform Proposals

June 13, 2023 by Julia Gillert, Els Janssens and Magda Tovar 2 Mins Read

As previously covered in this blog, on 26 April 2023 the European Commission published a set of proposals…

In EU Pharmaceutical Package

Supply Chain Protection: What do the EU Reform Proposals Look Like and do They go Far Enough?

June 13, 2023 by Julia Gillert, Els Janssens and Magda Tovar 3 Mins Read

As already well noted on this blog, on 26 April 2023 the European Commission published a set of…